Bridging the Gap in Longevity Care: Insights from Dr. Hilary Lin
In a rapidly evolving field, there remains a significant gap between scientific advancements in longevity medicine and the accessibility of those innovations in traditional healthcare settings. Dr. Hilary Lin shares her journey and insights on how to navigate that landscape, with a focus on scalable, personalised care.
Listen on SpotifyUnderstanding longevity medicine
Dr. Lin highlights exciting discoveries — mTOR inhibition, NAD+ restoration — but points out a critical issue: patients seeking help often receive generic advice despite the advances available. A patient with chronic fatigue may only be told to rest and take multivitamins, missing tailored interventions that could meaningfully improve their quality of life.
The bottleneck of delivery
The primary bottleneck in longevity is not the discovery of new treatments but the delivery of them. Traditional healthcare, restricted by insurance structures, focuses on treating illness rather than promoting longevity. The result is burnout among physicians and inadequate care for patients who want to optimise rather than just react.
The shift towards decentralisation
Dr. Lin advocates for a decentralised model that empowers patients. By removing insurance gatekeepers, patients can gain direct access to personalised care. As people become more informed about their own health, they should have the agency to make decisions without navigating referrals and approvals.
The role of technology
Just as AI is democratising access to information, similar advances in healthcare can empower individuals to understand and manage their own health better. The challenge is maintaining safety guardrails so patients are informed about their choices rather than overwhelmed by them.
Lessons from mental health navigation
Dr. Lin's experience with her first startup, Curio, focused on mental health navigation, provides valuable lessons on scaling healthcare services. People are reluctant to invest in mental health when they are not in crisis. Psychedelic-assisted therapy showed significant benefits, but accessibility remains the bottleneck — a pattern that repeats throughout longevity care.
Key takeaways
The urgent task is to transform how longevity and preventive care are delivered, not only what is delivered. Decentralisation and technology can empower both patients and providers. Address delivery bottlenecks. Embrace personalised medicine. Ensure patients are well-informed about their choices.